Document is current
Any future updates will be listed below
-
Authors
Ehlers, Femke A. I.
Blise, Katie E.
Betts, Courtney B.
Sivagnanam, Shamilene
Kooreman, Loes F. S.
Hwang, E. Shelley
Bos, Gerard M. J.
Wieten, Lotte
Coussens, Lisa M.
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32CA254888)
National Institutes of Health (U2CCA233254-01, R01CA222508)
Susan G. Komen
Kankeronderzoeksfonds Limburg
National Foundation for Cancer Research
Knight Cancer Institute, Oregon Health and Science University
- License Information
-
More Information
Article History
Received: 25 August 2024
Accepted: 12 January 2025
First Online: 24 January 2025
Declarations
:
: Cohort 1 samples were obtained from Duke University, Durham, USA. Informed consent was obtained from all human subjects included in this study. The study protocol was approved by the ethics committee IRB of Duke University (Pro00034242). Cohort 2 samples were obtained by Maastricht University Medical Center+, Maastricht, The Netherlands. The collection, storage, and use of tissue and patient data were performed in agreement with the “Code for Proper Secondary Use of Human Tissue in the Netherlands” and approved by the local ethics committee (METC 2019 − 1154).
: Not applicable.
: C.B. Betts is an employee of, and holds equity in, Akoya Biosciences, Inc. L.M. Coussens has received reagent support from Cell Signaling Technologies, Syndax Pharmaceuticals, Inc., ZielBio, Inc., and Hibercell, Inc.; holds sponsored research agreements with Syndax Pharmaceuticals, Hibercell, Inc., Prospect Creek Foundation, Lustgarten Foundation for Pancreatic Cancer Research, Susan G. Komen Foundation and the National Foundation for Cancer Research; is on the Advisory Board for Carisma Therapeutics, Inc., CytomX Therapeutics, Inc., Kineta, Inc., Hibercell, Inc., Cell Signaling Technologies, Inc., Alkermes, Inc., Raska Pharma, Inc., NextCure, Guardian Bio, AstraZeneca Partner of Choice Network (OHSU Site Leader), Genenta Sciences, Pio Therapeutics Pty Ltd., and Lustgarten Foundation for Pancreatic Cancer Research Therapeutics Working Group, Inc.
